Senseonics’ Eversense® obtains non-adjunctive labeling claim in U.S.
Category: #health  By Pankaj Singh  Date: 2019-12-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Senseonics’ Eversense® obtains non-adjunctive labeling claim in U.S.

Senseonics Holdings, Inc., a US-based medical device startup company recently announced that users of its Eversense CGM (continuous glucose monitoring) system can now use the new Eversense CGM mobile application for dosing insulin based on the readings from their Eversense System without requiring to perform a validating blood-glucose fingerstick measurement test.

For the record, Senseonics Holdings, is a medical technology pioneering the development, as well as commercialization, of the only long-term implantable CGM (continuous glucose monitoring) system for diabetic population.

The Eversense continuous glucose monitoring system comprises of a fluorescence sensor, a smart transmitter that is worn over the sensor to aid data communication, and lastly a mobile app for displaying glucose trends, values and alerts. The system does not only feature the first long-term, first implantable continuous glucose monitoring sensor but is also the first to include a smart transmitter, which provides wearers with subtle on-body vibratory alerts for low and high glucose levels.

In a brief in-office procedure,  health care providers can insert this sensor subcutaneously in the upper arm of the patient. The systems can be recharged, removed, or re-attached to the skin without discarding the sensor.

Tim Goodnow, President & CEO at Senseonics was reportedly quoted saying that since new Eversense app is available from the Google Play and Apple App stores, the users in the U.S. can take full advantage of being in a position to make treatment decisions without the need to test their blood glucose levels. He added saying that only after a year of entering the market, the company has made a remarkable achievement in the form of the new enhanced user experience by providing this updated indication in the Eversense technology.

Francine R. Kaufman, Endocrinologist, MD, CMO & Board member at Senseonics stated that Eversense users will now have the added benefit with the Eversense app of not having to interrupt their daily activities like eating or exercising for fingerstick before taking insulin.
 

Source Credit: https://www.senseonics.com/investor-relations/news-releases/2019/12-02-2019-210406927



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...